B oth US and European guidelines define severe aortic stenosis (AS) by a peak aortic jet velocity ≥4 m/s, mean Doppler gradient ≥40 mm Hg, aortic valve area (AVA) <1 cm 2 , and AVA indexed by body surface area (AVA/BSA) <0.6 cm 2 / m 2 in patients with preserved (≥50%) left ventricular ejection fraction (EF) and normal transvalvular flow. 1,2 Despite these apparently straightforward criteria, inconsistencies in the echocardiographic grading of AS are frequently encountered in routine practice, and there is a growing body of evidence showing that AVA could overestimate the severity of AS compared with flow-dependent parameters. 3, 4 Because all cardiovascular structural and functional parameters scale with body size, one reasonable attempt to reduce discrepancies between flow-independent and flow-dependent AS severity parameters and increase the diagnostic performance of AVA is to normalize it to BSA. The reliability of AVA/BSA as diagnostic parameter in AS is subject to debate because of the confounding effect of the acquired fat tissue that does not interact with AVA. 5 Moreover, the 0.6 cm 2 /m 2 AVA/BSA guideline-recommended cutoff is based on old studies including limited number of patients 6-8 and has not been validated to date by outcome studies. Recently, in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) population, it has been shown that the use of the 0.6 cm 2 /m 2 cutoff increases by ≈10% the frequency of severe AS compared with the 1 cm 2 AVA cutoff. 9 It has also been suggested that a lower AVA/BSA cutoff might reduce grading inconsistencies and improve event prediction. [9] [10] [11] 
Indexed Aortic Valve Area and Outcome in Aortic Stenosis
2 French tertiary centers (Amiens and Lille) are 3-fold: (1) to demonstrate the value of the classical AVA indexation to BSA for outcome prediction in asymptomatic AS; (2) to identify the AVA/BSA cutoff that best predicts high risk of events during follow-up; and (3) to compare the predictive ability of AVA/ BSA with that other normalized AVA indexes (AVA/height, AVA/weight, and AVA/body mass index [BMI] ).
Methods

Study Population
Consecutive patients aged ≥18 years diagnosed with ≥mild AS and EF ≥50% between 2000 and 2012 were prospectively identified and included in an electronic database. We excluded (1) >mild aortic and mitral regurgitation; (2) patients with prosthetic valves, congenital heart disease (with the exception of bicuspid aortic valves), supravalvular or subvalvular AS, or dynamic left ventricular tract obstruction;
(3) patients with symptoms by history or on exercise testing including dyspnea, angina, and syncope; and (4) patients who denied authorization for research participation. The present analysis focuses on 289 asymptomatic patients with AVA ≤1.3 cm 2 at the time of diagnosis. A comorbidity index summating the patient's individual comorbidities was calculated. 12 Coronary artery disease was defined by the presence of documented history of acute coronary syndromes, significant coronary artery disease confirmed by coronary angiography, or history of coronary revascularization. 12 We obtained institutional review board authorizations before conducting the study. All subjects gave informed consent to participate to the research. The study was conducted in accordance with institutional policies, national legal requirements, and the revised Helsinki declaration.
Echocardiography
All patients underwent a comprehensive Doppler-echocardiographic study, using commercially available ultrasound systems. Peak aortic velocity was recorded using continuous-wave Doppler in several acoustic windows (apical 5-chamber view, right parasternal, suprasternal, and epigastric). 12 Pressure gradients were calculated using the simplified Bernoulli equation. 12 AVA was calculated by the continuity equation 12 and was normalized to body size (AVA/BSA, AVA/ height, AVA/weight, and AVA/BMI). Stroke volume was calculated by multiplying the area of left ventricular outflow tract by the outflow tract time-velocity integral. Aortic valve calcification was assessed according to Rosenhek et al. 13 When patients were in sinus rhythm 3 cardiac cycles were averaged for all measures. For patients in atrial fibrillation, 5 cardiac cycles were averaged.
Left ventricular dimensions were assessed from parasternal longaxis views by 2-dimensional-guided M-mode using the leading edge methodology at end-diastole and end-systole. EF was calculated using Simpson biplane method. Left ventricular mass was indexed for BSA. 12 
Clinical Decision and Follow-Up
After an initial medical management, clinical follow-up, transthoracic echocardiography, and exercise test (in patients able to exercise) were performed. Information on follow-up was retrospectively obtained by direct patient interview and clinical examination and by repeated follow-up letters, questionnaires, and telephone calls to physicians, patients, and (if necessary) next of kin. Cases were accrued for 2000 to 2012. All patients had at least 2 years of follow-up. Moreover, the follow-up was complete up to death, to the end of the study (2014) or at least 5 years in 240 patients (83%). Median (25th, 75th percentile) follow-up was 37 (17, 74) months. The first outcome variable was the time to occurrence of the composite end point, defined as all-cause death or the need for aortic valve replacement. The second outcome variable was the occurrence of all-cause death during the entire follow-up. Clinical decisions on medical management and referral for surgery were made by the heart team with the approval of the patient's cardiologist based on the European Society of Cardiology guidelines. 14, 15 Indications for aortic valve replacement were symptom development, EF <50%, or occurrence of symptoms during an exercise test.
Statistical Analysis
Continuous variables were expressed as mean value±1 SD or median (25th, 75th percentiles), and categorical variables were summarized as frequency percentages and counts. The study population was divided in groups according to tertiles of AVA/BSA, AVA/height, AVA/ weight, and AVA/BMI. The relationship between baseline continuous baseline variables and the 3 groups was explored using 1-way ANOVA tests (for normally distributed variables) or Kruskal-Wallis tests (for non-normally distributed variables). Pearson χ 2 statistic or Fisher exact test was used to examine the association between the 3 groups and baseline categorical variables. The significance between the highest tertile and the others was examined if there was a significant difference across tertiles. Individual differences were compared with Mann-Whitney U tests (with Bonferroni correction for multiple comparisons) and Tukey tests for normally distributed data.
Event rates ±1 SE were estimated according to the Kaplan-Meier method and compared with 2-sided log-rank tests. Univariate and multivariable analyses of time to events were performed using Cox proportional hazards models. We did not use model-building techniques and entered in the models covariates considered of potential prognostic impact on an epidemiological basis. These covariates were as follows: age, sex, comorbidity index (not including age), history of hypertension, coronary artery disease, EF, and history of atrial fibrillation. The model was further adjusted for peak aortic jet velocity (4 m/s cutoff) in the second step. Age, comorbidity index, EF, and peak aortic jet velocity were used in the multivariable models as continuous variables. The proportional hazards assumption was confirmed using statistics and graphs based on the Schoenfeld residuals. For continuous variables, the assumption of linearity was assessed by plotting residuals against independent variables. Penalized smoothing splines (P-splines) were used to illustrate the association of indexed AVA parameters as continuous variables and the risk of events during follow-up. The overall performance of the multivariable models was assessed using the Akaike Information Criterion, the model with lowest Akaike Information Criterion value being the best fitting model. The increased discriminative value of normalized AVA indexes was investigated by estimating the C statistics for models with and without normalized AVA indexes. The integrated discrimination improvement (IDI) and the net reclassification improvement (NRI) were determined to further describe the added utility of each normalized AVA index when added to the multivariable model. 16, 17 The IDI measures the new model's ability to improve integrated sensitivity without compromising integrated specificity. The NRI measures the appropriateness of patient reclassification based on the probability of death at selected time points. In the absence of well-verified risk categories in asymptomatic AS, we used the continuous NRI method that does not require a previous definition of strata risk, thus considering the change in the estimation prediction as a continuous variable. The continuous NRI captures the marginal strength of the new predictor after accounting for correlations with variables included in the baseline model. 17 NRI and IDI were computed at 24 months and at the end of follow-up using the R package survIDINRI developed by Hajime Uno. 18 Finally, we conducted subgroup analyses to determine the homogeneity of the association of each normalized AVA index and the outcome variable. The analyzed subgroups with small body size were as follows: BSA ≤1.6 m 2 , height ≤1.55 m, weight ≤50 kg, and BMI ≤20 kg/m 2 . For mortality analyses, we used the entire follow-up (with conservative and surgical treatment), and the effect of surgery was analyzed as a time-dependent covariate. 19 All P values are results of 2-tailed tests. Data were analyzed with SPSS 13.0 (SPSS Inc., Chicago, IL), STATA (version 12, StataCorp LP, College Station, TX), and the R software (The R Foundation for Statistical Computing). The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the article as written.
Results
Baseline Characteristics
The demographic and clinical characteristics of the 289 patients, overall and according to AVA/BSA tertiles are presented in Table 1 . atients in the lower AVA/BSA tertiles were taller, more often overweight, had greater BSA and BMI. Hypertension was more frequent among patients in the highest AVA/BSA tertile ( Table 1) .
As regard to echocardiographic variables, patients in the lowest AVA/BSA tertile had, higher peak aortic jet velocity and mean gradient, increased valvuloarterial impedance, lower dimensionless index, and greater left atrial size ( Table 2 ). Left ventricular outflow tract diameter, left ventricular mass, and EF were similar across AVA/BSA tertiles. Compared with the highest tertile, patients in the lowest tertile had decreased cardiac output, lower indexed stroke volume, yet greater left ventricular end-systolic diameter ( Table 2) .
Demographic, clinical, and echocardiographic characteristics of the study patients according to AVA/height, AVA/ weight, and AVA/BMI tertiles are presented in the Tables I through III in the Data Supplement.
Normalized AVA Parameters and Risk of Events After Diagnosis
The total number of events recorded during follow-up was 206 (76 deaths including 27 deaths of cardiac causes and 130 aortic valve replacements). Fourteen patients who underwent aortic valve replacement died during the postoperative follow-up.
In patients who underwent surgery, aortic bioprostheses were used in 80% of cases (n=104) and 33 patients had at least one associated coronary artery by-pass graft at the time of surgery. During the first 2 years after diagnosis, 77 aortic valve replacements and 47 deaths had occurred. The shape of the relationship between each AVA parameter and the risk of events during follow-up is presented in Figure 1 .
AVA Normalized to BSA
Two-year event-free survival was 74±4% for the third AVA/ BSA tertile (>0.53 cm 2 /m 2 ), 72±5% for the second tertile (0.40-0.53 cm 2 /m 2 ), and 38±5% for the first tertile (<0. Table 3 ; Figure 3A ). Results were unchanged after further adjustment by peak aortic jet velocity (Table 3) .
When patients were classified according to predefined AVA/ BSA cutoffs, including the 0.6 cm 2 /m 2 guideline-recommended cutoff used to define severe AS ( Figure 4A ), we observed similar 2-year event-free survival for AVA/BSA >0.6 cm 2 /m 2 (71±6%), 0.5 to 0.6 cm 2 /m 2 (79±5%), and 0.4 to 0.49 cm 2 /m 2 (72±5%) and poor outcome for AVA/BSA <0.4 cm 2 /m 2 (2-year event-free survival: 38±5%). After adjustment for covariates, the outcome of AVA/BSA group >0.6 cm 2 /m 2 was comparable to that of the 0.5 to 0.6 cm 2 /m 2 AVA/BSA group (adjusted HR, 0.89[0.78-3.75]) 
AVA Normalized to Height
The 2-year survival free of events of patients classified according to AVA/height tertiles is presented in Figure 2B . Eighty one percent of patients in the lowest AVA/height tertile had AVA/BSA <0.40 cm 2 /m 2 . Two-year event-free survival was 75±5% for the third tertile (>0.6 cm 2 /m), 73±5% for the second tertile (0.45-0.6 cm 2 /m), and 33±5% for the first tertile (<0.45 cm 2 /m; Figure 2B ). Eight-year event-free survival curves are presented in the Figure IB in the Data Supplement. The excess risk of events associated with AVA/height <0.45 cm 2 /m was also observed after adjustment for age, sex, comorbidity, hypertension, coronary artery disease, atrial fibrillation, and EF (adjusted HR, 3.99 [2.42-6.60]; Table 3 ; Figure 3B ), whereas the outcome of patients in the second and third tertiles was identical (adjusted HR, 1.17 [0.66-2.06]; Table 3 ; Figure 3B ). Further adjustment for peak aortic jet velocity did not change these relationships (Table 3) . When patients were classified according to predefined AVA/height cutoffs ( Figure 5A ), 2-year event-free survival was comparable for AVA/height >0.65 cm 2 /m (79±5%), 0.55 to 0.65 cm 2 /m (73±5%), and 0.45 to 0.54 cm 2 /m (69±6%), whereas patients with AVA/height <0.45 cm 2 /m had dismal outcome (2-year event-free survival: 33±5%). After adjustment, the event-free survival of patients with AVA/height >0.65 cm 2 /m was comparable to that of patients with AVA/ height between 0.55 and 0.65 cm 2 Figure 5B ). Further adjustment by peak aortic jet velocity did not significantly impact the results. Figure 2C presents the 2-year event-free survival of patients according to AVA/weight tertiles. Although the second and third tertiles had identical prognosis, the first tertile was associated with significantly poorer outcome. Two-year event-free survival was 72±5% for the third AVA/weight tertile (>0.14 cm 2 /kg), 71±5% for the second tertile (0.01-0.14 cm 2 /kg) and 37±5% for the first tertile (<0.01 cm 2 /kg; Figure 2C ). Eightyear event-free survival curves are presented in the Supplemental Figure IC in the Data Supplement. After adjustment for age, sex, comorbidity, hypertension, coronary artery disease, atrial fibrillation, and EF, the first tertile showed excess risk of events compared with the third tertile (adjusted HR, 3.37 [2.07-5.49]; Table 3 ; Figure 3C ). Supplemental adjustment for peak aortic jet velocity confirmed the poor outcome of patients in the first tertile (Table 3) .
AVA Normalized to Weight
AVA Normalized to BMI
Event-free survival according to AVA/BMI tertiles showed a similar pattern ( Figure 1D ). Two-year event-free survival was 38±5% for the first tertile (<0.029 cm 2 /kg per meter square) and significantly better for the second (0.029-0.038 cm 2 /kg per meter square) and third (>0.038 cm 2 /kg per meter square) tertiles (71±5% and 73±5%, respectively, Figure 2D ). Eightyear event-free survival curves are presented in the Supplemental Figure ID in the Data Supplement. The multivariable models confirmed excess risk of events for the first tertile and comparable outcome for the other 2 tertiles (Table 3 ; Figure 3D ). 
Comparison of the Prognostic Value of Normalized AVA by the Various Body Size Indexes
We conducted several analyses to evaluate the added value for event prediction (death or aortic valve replacement) of introducing each normalized AVA index (AVA/BSA, AVA/ height, AVA/weight, and AVA/BMI) as covariate in a Cox proportional hazard model including age, sex, comorbidity, hypertension, coronary artery disease, atrial fibrillation, and EF. Akaike Information Criterion was lowest for the model including AVA/height indicating best model fit ( Table 4 ). The effects on the C statistics when adding normalized AVA indexes to the basic model were important for AVA/height and AVA/BSA, slightly better for AVA/height (Table 4) 
Subgroup Analyses
The predictive value of AVA/BSA and AVA/height was not influenced by age, sex, and left ventricular outflow tract diameter (all P for interaction >0.10). Among different subgroups with small body size, the only significant interaction was between AVA/BSA<0.40 cm 2 /m 2 and BMI (HR, 2.67 [1.99-3.60] in patients with BMI>20 kg/m 2 (n=271) and HR, 0.31 [0.16-1.54] in patients with BMI≤20 kg/m 2 (n=18); P for interaction 0.014). There was no interaction between outcome prediction of AVA/height and small body size indexes (all P for interaction >0.10). 
Normalized AVA Parameters and Risk of Death After Diagnosis
Two-year survival of patients with AVA/height ≥0.45 cm 2 /m was higher than those with AVA/height <0.45 cm 2 /m (85±2% versus 76±4%; P=0.053). For the other AVA parameters, 2-year survival rates were as follows: 84±2% versus 77±3% for AVA/BSA ≥0.40 versus <0.40 cm 2 /m 2 (P=0.06), 83±2% versus 78±4% for AVA/weight ≥0.01 versus <0.01 cm 2 /kg (P=0.11), and 83±2% versus 79±3% for AVA/BMI ≥0.029 versus <0.029 cm 2 /kg per meter square (P=0.13). On multivariable analysis, using the covariates of adjustment and surgery as time-dependent covariate the risk of all-cause death during follow-up was impressive with AVA/height <0.45 cm 2 /m (adjusted HR, 2.18 [1.28-3.71] for AVA/height <0.45 versus ≥0.45 cm 2 /m; Figure 6 ). The strength of the effect on mortality of the other normalized AVA parameters was lower, yet significant (adjusted HR, 
Discussion
The present study shows the powerful outcome implication of AVA normalized to body size. Among the 4 indexation methods, normalization to height shows the best predictive capacity in terms of reclassification and discrimination, with impressive excess event rate below the 0.45 cm 2 /m cutoff and no interaction between the outcome prediction of AVA/height and indexes of small body size. In terms of the mortality risk, the value of AVA/height <0.45 cm 2 /m is superior to that of other normalized indexes and is unaltered by adjustment for demographic, clinical, and echo variables. We also report that in the specific case of asymptomatic AS, the current 0.6 cm 2 / m 2 cutoff to define severe AS does not predict the occurrence of events after diagnosis. Our data show that asymptomatic patients with AVA/BSA <0.4 cm 2 /m 2 at the time of diagnosis have >60% event rate at 2 years, whereas higher AVA/BSA cutoffs result in comparable and preserved outcome, suggesting that AVA/BSA <0.4 cm 2 /m 2 truly identifies asymptomatic patients with AS at high risk.
In normal adults, cardiovascular structural and functional parameters exhibit considerable variability. 20 Several indexation methods have been proposed in an attempt to identify pathological conditions and distinguish them from normal variants. 20 The best indexation method is the subject to an ongoing debate, and although some reports suggest that linear adjustment of cardiac dimensions by body size measures might be flawed, this does not seem to hold for valve area, especially AVA. Indeed, older studies conducted in healthy volunteers 21 and recent data in patients with AS 22 strongly support linear adjustment of AVA by BSA showing that more sophisticated allometric indexations have no added predictive value in this setting. Indexation by BSA seems as a reasonable way to increase the sensitivity and specificity of a certain measure by eliminating the variability related to the effect of body size. 22 The use of the normalization by BSA has been criticized especially in patients with obesity where it corrects not only for body size but also for the acquired fat tissue. Early hemodynamic studies including significant number of congenital AS have shown that patients with AS and AVA <1 cm 2 have dismal outcome 7 and suggested that AVA should be corrected by BSA. 6, 23 Although contemporary outcome data supporting the prognostic value of AVA/BSA are scant, 9, 24 US and European guidelines 1,2 have included AVA/BSA among criteria for grading AS severity (ie, AVA/BSA <0.6 cm 2 /m 2 ). In a study including 103 asymptomatic patients with, AS, AVA/BSA was independently predictive of cardiac death and valve replacement. 24 Jander et al 9 have recently shown that among patients with AS the number of patients with AVA/BSA <0.6 cm 2 /m 2 is significantly greater than the number of patients with AVA <1 cm 2 and that the predictive accuracy for aortic valve events of the 2 parameters is almost identical. 9 Our results show that asymptomatic patients with AS in whom at the time of diagnosis AVA/BSA is <0.4 cm 2 /m 2 represent a high-risk group with >60% rate of events at 2 years. We also clearly demonstrate that in asymptomatic AS, the use of higher AVA/BSA cutoffs result in similar risk of events during follow-up. The predictive power of AVA/BSA <0.4 cm 2 /m 2 remains unaltered after adjustment for peak aortic jet velocity, which is universally recognized as a reliable severity marker in AS. Furthermore, according to our data, AVA normalization by height seems to have better predictive capacity than AVA/BSA, with ≈70% event rate at 2 years when AVA/height is below the 0.45 cm 2 /m cutoff. Importantly, in our study AVA/height was the only normalized index predictive of death during follow-up after adjustment for peak aortic jet velocity.
Asymptomatic patients with severe AS require careful follow-up and the identification of individuals at high risk for cardiovascular events is crucial. The general consensus is that asymptomatic patients with severe AS with abnormal exercise test, rapid progression, or severe valvular calcification might benefit of elective aortic valve replacement. 1, 2 Occurrence of symptoms has poor reliability in patients with limited physical activity, and left ventricular function impairment observed during close follow-up is associated with considerable risk that is not corrected after surgery. There is therefore an ongoing search for markers of high risk under medical management. Peak aortic jet velocity is currently the cornerstone of AS severity quantification and has definite prognostic value. 25, 26 Thus, peak aortic jet velocity >5.5 m/s defines patients with very severe asymptomatic AS with high risk of events at 2-year follow-up. 2 As regard to AVA, it has been reported that a cutoff of <1 cm 2 predicts unfavorable outcomes in a series including both asymptomatic and symptomatic patients. 27 The present study shows that patients with AS free of symptoms in whom AVA/BSA is <0.4 cm 2 /m 2 at the time of diagnosis incur high risk of events at 2 years. AVA/height <0.45 cm 2 /m allows better identification of these asymptomatic patients at high risk and therefore could replace AVA/BSA in routine clinical practice.
Strengths and Limitations
Information on follow-up was retrospectively obtained, and therefore our study has the inherent limitations of such analyses. The specific indications for surgery during follow-up were not collected in our database. However, diagnosis and follow-up was performed by cardiologists with expertise in valvular disease, and the surgical decisions were taken by the heart team in accordance with current practice guidelines. The calculation of the AVA by the continuity equation is prone to errors because of the difficult measure of the left ventricular outflow tract cross-sectional area because of the noncircular geometry or massive calcifications. 5 Aortic valve calcium score by computed tomography was not assessed systematically in our patients and therefore was not available for the outcome analyses. We studied exclusively asymptomatic patients with AS with preserved EF and without significant valve regurgitation. Further prospective studies are needed to validate the proposed cutoffs of the AVA indexes in asymptomatic patients with AS and to evaluate the role of AVA indexation in other subsets of patients with AS. The number of fatal events in this study is relatively low and therefore the association of normalized parameters with mortality should be confirmed by larger studies. The continuous NRI has limitations because its value depends only on the strength of its association with the outcome and not on the strength of the baseline model so that it may be considered a test of association rather than reclassification or model improvement. 28 
Conclusions
The present study shows that AVA indexation to body size is helpful for risk stratification in asymptomatic AS by identifying a subgroup of patients who are at high risk at short term under medical management. Using BSA indexation, the current recommendations define severe AS by AVA/BSA <0.6 cm 2 /m 2 , irrespective of the symptomatic status. We show that asymptomatic patients with AS with AVA/BSA <0.4 cm 2 /m 2 incur high risk of events. Further prospective and randomized studies are still needed to determine whether elective aortic valve replacement improves outcome in this high-risk subgroup of patients. Moreover, compared with AVA normalization to BSA, weight, or BMI, AVA/height shows better predictive performance with very high risk below the 0.45 cm 2 /m cutoff, strongly suggesting that height indexation should be preferred over BSA indexation for defining outcome in asymptomatic AS. However, in clinical practice, assessment of AS severity in asymptomatic patients should not rely on a single parameter but on a multiparametric approach incorporating data derived from transaortic gradients and velocities in addition to less flow-dependent indices such as AVA and indexed AVA. 
